X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-6-2024-62498.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216334
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217533
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216941
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-receives-final-approval-from-usfda-for-generic-mesalamine-extended-release-capsules/articleshow/95245927.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216967
https://www.expresspharma.in/sun-pharma-announces-us-fda-approval-for-generic-mesalamine-extended-release-capsules/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209970
https://www.biospace.com/article/releases/teva-announces-launch-of-its-generic-version-of-canasa-mesalamine-suppositories-to-treat-adults-with-active-ulcerative-proctitis-ulcerative-rectal-colitis-in-the-united-states/
https://farmabios.com/2021/01/12/pharmazell-update-on-new-mesalazine-production-building-in-vizag-india/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-18-2020-1605674129.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205654
https://www.expresspharma.in/latest-updates/lincoln-pharmaceuticals-receives-eu-gmp-approval/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-11-2020-1583989701.pdf
https://www.kyowakirin.com/media_center/news_releases/2020/pdf/e20200203_01.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210509
https://www.federalregister.gov/documents/2019/12/02/2019-25946/morton-grove-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-21-abbreviated-new-drug
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207271
https://www.biospace.com/article/releases/amring-pharmaceuticals-announces-the-launch-of-two-valued-pharmaceutical-generics/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202065
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207873
https://www.businesswire.com/news/home/20190510005380/en/Teva-Announces-Launch-Generic-Version-Delzicol%C2%AE-mesalamine
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211858
https://www.prnewswire.com/news-releases/launch-of-generic-lialda-delayed-release-tablets-expands-mylans-gastroenterology-product-offering-300767416.html
https://www.prnewswire.com/news-releases/mylan-adds-first-generic-for-canasa-rectal-suppository-to-growing-gastroenterology-portfolio-300767412.html
https://www.prnewswire.com/news-releases/mylan-adds-first-generic-for-canasa-rectal-suppository-to-growing-gastroenterology-portfolio-300767412.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208953
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208953
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207448
https://www.fiercepharma.com/pharma/lack-late-stage-assets-at-takeda-don-t-worry-shire-has-it-covered
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209970
https://www.businesswire.com/news/home/20180326006022/en/Teva-Announces-Launch-Generic-Version-Lialda%C2%AE-United
http://www.fdalawblog.net/2018/03/fda-says-no-180-day-exclusivity-forfeiture-for-generic-lialda-based-on-changed-bioequivalence-recommendations/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+FdaLawBlog+%28FDA+Law+Blog%29
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208362
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202065
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203286
http://www.business-standard.com/article/companies/cadila-healthcare-moraiya-plant-receives-eir-from-usfda-117062100598_1.html
http://www.biospectrumasia.com/news/25/9048/usfda-approves-the-generic-version-of-lialda-of-an-indian-drug-firm-zydus-cadila.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-for-mesalamine-tablets/articleshow/59031455.cms
http://economictimes.indiatimes.com/news/industry/healthcare/biotech/healthcare/maternal-education-fights-malaria-better-than-vaccine-study/articleshow/58608375.cms
https://www.pharmacompass.com/pdf/news/Delzicol-Mesalamine-Allergan-Qualicaps-V-Teva-Pharmaceuticals-Usa-1494842920.pdf
http://www.pharma-excipients.ch/2016/09/26/pectin-silica-gels-as-matrices-for-controlled-drug-release-in-gastrointestinal-trac/
http://www.in-pharmatechnologist.com/Drug-Delivery/Shire-to-appeal-court-decision-in-favour-of-Zydus-Cadila-generic
https://www.pharmacompass.com/pdf/news/forest-labs-mesalamine-approved-in-us-1474376566.pdf
http://www.pharma-excipients.ch/2016/08/09/tailoring-the-mucoadhesive-and-sustained-release-characteristics-of-mesalamine-loaded-formulations-for-local-treatment-of-distal-forms-of-ulcerative-colitis/
Market Place
Share 
